The DIABLO Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa human cervical adenocarcinoma cells. This product features targeted disruption of the DIABLO gene (SMAC) via CRISPR/Cas9-mediated genome editing, generating a heterogeneous pool of cells with collective loss of DIABLO protein expression. The polyclonal format preserves cellular diversity while enabling robust investigation of DIABLO-dependent apoptotic signaling in a cancer-relevant background.
HeLa cells are HPV18-positive epithelial cells from a cervical adenocarcinoma, widely used as a model for cancer biology and apoptosis research. Their well-characterized genomic landscape and dysregulated apoptotic pathways provide a physiologically relevant context to study pro-apoptotic factors like DIABLO/SMAC. This host background enables assessment of how DIABLO loss impacts cell death signaling and therapeutic resistance in a cervical cancer setting.
DIABLO/SMAC is a mitochondrial pro-apoptotic protein released upon apoptotic stimuli to promote cell death by antagonizing inhibitor of apoptosis proteins (IAPs). Following mitochondrial outer membrane permeabilization, DIABLO and cytochrome c are co-released; cytochrome c activates Apaf-1 and caspase-9, while DIABLO binds and inhibits XIAP, cIAP1, cIAP2, and Survivin, thereby lifting IAP-mediated suppression of caspases-3, -7, and -9. DIABLO release is governed by upstream BAX/BAK and BH3-only proteins, and its function intersects with HtrA2/Omi. This signaling network positions DIABLO as a central coordinator of both intrinsic and extrinsic apoptotic pathways.
In HeLa cells, which often overexpress IAPs, DIABLO knockout attenuates mitochondrial apoptosis and creates a sensitized model for probing IAP function and screening IAP antagonists. This loss-of-function system illuminates how cervical cancer cells evade cell death and reveals vulnerabilities that could be targeted to restore apoptotic sensitivity. Additionally, the HPV18-positive background offers opportunities to explore viral modulation of DIABLO-dependent apoptosis.
Applications include Western blotting of DIABLO and IAPs, caspase activity assays, and apoptosis quantification by TUNEL or Annexin V flow cytometry. Co-immunoprecipitation can examine DIABLO?CIAP interactions, while cytochrome c release assays assess mitochondrial permeabilization. The knockout cells are suitable for studying cancer drug resistance, ischemic injury, neurodegeneration, and autoimmune disorders, as well as developing IAP inhibitors and other pro-apoptotic therapeutics. For additional information, please contact Ascent Research.
